Q2 - 2022: Crowdsale

-> INVESTORS BE WARNED! WE DO NOT HAVE A BALANCE SHEET, INCOME STATEMENT, OR CASH FLOW STATEMENT. THE REASON WHY IS THAT NO ONE HAS EVER LAUNCHED A METAVERSE BUSINESS IN THE PHARMACEUTICAL SECTOR<-
THE IMPLICATIONS ARE HUGE: Our new, never before been done, collaborative platform for the development of new medicines, would change the course of history for medicine: and especially for the poor and disenfranchised of the world, such as those who suffered from #Coronavirus Vaccine-inequity.
With Pharmaceutical R&D Investments down in Q1 2022 due to the strain of COVID, as well as its profit opportunity to the PHARMA industry: We believe our Product Thesis proposes the best way to "course correct" these investment numbers.
DISCLAIMER: As of this date, we seek only Accredited Investors and partners such as Fortune 1,000 Companies, governments, universities, and globally competitive existing pharmaceutical companies, all of whom have the Fractionalized Intellectual Property (IP) NFT's source patents assigned to them. We need to begin to think in genetics, pharmacogenetics, and in terms of compounds and molecules. PHARMA Token investments are considered a High Risk Investment .
Additionally, this risk lies in the highly-controversial (from a legal perspective) Blockchain Industry, where Regulations are institutionally adopted, but Regulatory and Compliance constantly lie in a "Grey Area" that constantly changes as a moving target, as per disclosure, which the reader should be aware of. PHARMA Token is classified as a #derivative, and #ALTCoin, and a #UtilityToken by US Regulatory and Compliance Agencies, all of whom we contacted as part of our US Government lobbying effort throughout the #COVID19Pandemic .
This project's pharma, blockchain, NFT, and all other initial, Non-Profit R&D was done as part of a graduate school thesis which stemmed from a necessary #COVID19Response on the side of #TransparentData in the Pharmaceutical, Life Science, and Nutrition Science industries.
COVID was politicized, disorganized, and in #DataScience Chaos. We iterated the approach to get #BioTech right.